Pavel Mozgunov

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Saye Khoo, Richard J. Fitzgerald, Sean Ewings et al. · Journal of Antimicrobial Chemotherapy · 2021 · 111 citations · Full text

Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial

Saye Khoo, Richard J. Fitzgerald, Geoffrey Saunders et al. · The Lancet Infectious Diseases · 2022 · 76 citations · Full text

Vaccination, Covid-19 Pandemic, Vaccine Trial +8

An Information Theoretic Phase I–II Design for Molecularly Targeted Agents That Does Not Require an Assumption of Monotonicity

Pavel Mozgunov, Thomas Jaki · Journal of the Royal Statistical Society Series C (Applied Statistics) · 2018 · 34 citations · Full text

Pharmacotherapy, Small Molecules, Molecular Design +17

An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Lauren Walker, Richard J. Fitzgerald, Geoffrey Saunders et al. · Clinical Pharmacology & Therapeutics · 2021 · 25 citations · Full text

Loss functions in restricted parameter spaces and their Bayesian applications

Pavel Mozgunov, Thomas Jaki, Mauro Gasparini · Journal of Applied Statistics · 2019 · 18 citations · Full text

Squared Error Loss, Bayesian Statistics, Bayesian Statistic +13